Join BrainStorm Cell Therapeutics for a webinar featuring Dr. Terry Heiman-Patterson, a key opinion leader (KOL) from the Lewis Katz School of Medicine at Temple University, who will discuss the current treatment landscape and advances for patients with amyotrophic lateral sclerosis (ALS).

Dr. Heiman-Patterson will be joined by BrainStorm’s leadership team, who will share updates on the company’s planned Phase 3b registrational clinical trial, NurOwn® (autologous MSC-NTF cells), and future development plans.

The event will include a review of BrainStorm’s proprietary and validated autologous cellular technology platform, NurOwn, and an overview of the anticipated milestones for the Phase 3b trial. Successful completion of the randomized portion of this trial (Part A) is expected to support a Biologic License Application (BLA) for NurOwn.

A live Q&A session will follow the formal presentations.